Exp Clin Endocrinol Diabetes 2007; 115(1): 58-61
DOI: 10.1055/s-2007-955098
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Use of the New Indicator Test (Neuropad®) for the Assessment of the Staged Severity of Neuropathy in Type 2 Diabetic Patients

N. Papanas 1 , G. Giassakis 2 , K. Papatheodorou 1 , D. Papazoglou 1 , C. Monastiriotis 1 , D. Christakidis 3 , H. Piperidou 2 , E. Maltezos 1
  • 1Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
  • 2Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
  • 3Diabetic Department, University Hospital of Alexandroupolis, Greece
Further Information

Publication History

Received 14.7.2006 First decision 21.8.2006

Accepted 21.8.2006

Publication Date:
07 February 2007 (online)

Abstract

The new indicator test for sudomotor function (Neuropad®) has been shown to represent a highly sensitive and reproducible tool for the diagnosis of diabetic peripheral neuropathy. This study aimed to examine the utility of the indicator test in the assessment of the staged severity of neuropathy in patients with type 2 diabetes mellitus. The study included 120 type 2 diabetic patients (58 men) with a mean age of 67.3±5.9 years and a mean diabetes duration of 13.1±3.2 years. Neuropathy was diagnosed and staged by clinical examination and nerve conduction study, according to the Michigan classification system. Patients were also examined with the indicator test, applied on the plantar aspect of the feet. Time until complete colour change of the test was recorded and stratified into deciles according to the spread of measurements in the study population. Neuropathy was staged as class 0 in 37 patients, class 1 in 44 patients, class 2 in 28 patients and class 3 in 11 patients. Time until complete colour change was 436.5±62.9, 740±88.1, 1192.5±161 and 1817.3±127.4 seconds in patients staged as class 0, 1, 2 and 3 respectively (p=0.001). Use of a threshold lower than 530 seconds until complete colour change had 97% sensitivity and 100% specificity for diagnosis of class 0 neuropathy. Use of a threshold lower than 1000 seconds until complete colour change had 100% sensitivity and 97% specificity for class 1 neuropathy. A threshold lower than 1440 seconds had 93% sensitivity and 100% specificity for class 2 neuropathy. A threshold above 1440 seconds had 100% sensitivity and 99% specificity for class 3 neuropathy. A highly significant (Kendall's tau-b=0.848, p=0.001) correlation was shown between time until complete colour change of the test and Michigan class of neuropathy.

Conclusions:It appears that the indicator test contributes substantially to the assessment of the staged severity of neuropathy in patients with type 2 diabetes mellitus. There is excellent agreement between the indicator test and the Michigan classification system. These results suggest a role for the indicator test in the assessment of diabetic neuropathy.

References

  • 1 American Diabetes Association and American Academy of Neurology . Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy.  Diabetes. 1988;  37 1000-1004
  • 2 Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI).  Diabetes Care. 1996;  19 904-905
  • 3 Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture.  Diabetologia. 2004;  47 1343-1353
  • 4 Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers.  N Engl J Med. 2004;  351 48-55
  • 5 Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. American Diabetes Association . Diabetic neuropathies: a statement by the American Diabetes Association.  Diabetes Care. 2005;  28 956-962
  • 6 Budavari S, O’Neil MJ, Smith A, Heckelman PE, Kinneary JF. (Eds). .The Merck Index. An encyclopaedia of chemicals, drugs and biologicals. 12th Edition. Merck Research Laboratories, New Jersey 1996 p. 2503
  • 7 Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review.  Am J Health Syst Pharm. 2004;  61 160-173
  • 8 Dyck PJ. Detection, characterization and staging of polyneuropathy: assessed in diabetics.  Muscle Nerve. 1988;  11 21-32
  • 9 Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton III LJ, O’Brien PC, Litchy WJ, Windeback AJ, Smith BE, Low PA, Service FJ, Rizza RA, Zimmerman BR. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.  Neurology. 1991;  41 799-807
  • 10 Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.  Neurology. 1997;  49 229-239
  • 11 Edmonds ME. The diabetic foot, 2003.  Diabetes Metal Res Rev. 2004;  20 ((Suppl 1)) S9-S12
  • 12 Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusiano F. the Italian Diabetic Neuropathy Committee . A multicenter study on the prevalence of diabetic neuropathy in Italy.  Diabetes Care. 1997;  20 836-843
  • 13 Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy.  Diabetes Care. 1994;  17 1281-1289
  • 14 Manes C, Mikoudi K, Sossidou E, Pigas G, Karagianni D, Skoutas D, Fotiadis S. Evaluation of a new indicator plaster in identifying diabetic patients at risk of foot ulceration.  Diabetologia. 2004;  47 ((Suppl 1)) A 376
  • 15 Marinou K, Maggana S, Liatis S, Nikolopoulos A, Diakoumopoulou E, Tentolouris N. et al . Usefulness of the indicator plaster Neuropad for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus.  Diabetologia. 2005;  48 ((Suppl 1)) A 995
  • 16 Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, Monastiriotis C, Maltezos E. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients.  Exp Clin Endocrinol Diabetes. 2005;  113 195-198
  • 17 Papanas N, Papatheodorou K, Papazoglou D, Christakidis D, Monastiriotis C, Maltezos E. Reproducibility of the new indicator test for sudomotor function (Neuropad) in patients with type 2 diabetes mellitus: short communication.  Exp Clin Endocrinol Diabetes. 2005b;  113 577-581
  • 18 Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJM. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings.  Diabetes Care. 1999;  22 157-162
  • 19 Veves A, Manes C, Murray HJ, Young MJ, Boulton AJ. Painful neuropathy and foot ulceration in diabetic patients.  Diabetes Care. 1993;  16 1187-1189
  • 20 Young MJ, Boulton AJM, MacLeod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.  Diabetologia. 1993;  36 150-154
  • 21 Zick R, Schäper Th, Deeters U. Periphere diabetische Neuropathie. Die Schweißsekretion am Fuß messen.  Klinikarzt. 2003;  32 192-194

Correspondence

N. Papanas

Ethnikis Antistasis 44

Alexandroupolis 68100

Greece

Phone: +30/25/510 84 97 2

Fax: +30/25/510 74 72 3

Email: papanasnikos@yahoo.gr

    >